EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 179 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $0 | – | 0 | -100.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 8 | -92.0% | 0.00% | – |
| Q3 2019 | $6,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $6,000 | +20.0% | 100 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | +25.0% | 100 | 0.0% | 0.00% | – |
| Q4 2018 | $4,000 | -60.0% | 100 | -33.3% | 0.00% | -100.0% |
| Q3 2018 | $10,000 | -50.0% | 150 | -40.0% | 0.00% | -50.0% |
| Q2 2018 | $20,000 | -71.8% | 250 | -81.5% | 0.00% | -66.7% |
| Q1 2018 | $71,000 | -38.3% | 1,350 | -37.2% | 0.01% | -40.0% |
| Q4 2017 | $115,000 | -86.2% | 2,150 | -84.6% | 0.01% | -89.5% |
| Q3 2017 | $833,000 | -13.6% | 13,975 | +14.3% | 0.10% | -24.6% |
| Q2 2017 | $964,000 | +45.2% | 12,225 | +52.8% | 0.13% | +31.2% |
| Q1 2017 | $664,000 | – | 8,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |